BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

82 related articles for article (PubMed ID: 17372272)

  • 21. LY303511 (2-piperazinyl-8-phenyl-4H-1-benzopyran-4-one) acts via phosphatidylinositol 3-kinase-independent pathways to inhibit cell proliferation via mammalian target of rapamycin (mTOR)- and non-mTOR-dependent mechanisms.
    Kristof AS; Pacheco-Rodriguez G; Schremmer B; Moss J
    J Pharmacol Exp Ther; 2005 Sep; 314(3):1134-43. PubMed ID: 15923340
    [TBL] [Abstract][Full Text] [Related]  

  • 22. L6 myoblast differentiation is modulated by Cdk5 via the PI3K-AKT-p70S6K signaling pathway.
    Sarker KP; Lee KY
    Oncogene; 2004 Aug; 23(36):6064-70. PubMed ID: 15208659
    [TBL] [Abstract][Full Text] [Related]  

  • 23. A comprehensive immunohistochemical and molecular approach to the PI3K/AKT/mTOR (phosphoinositide 3-kinase/v-akt murine thymoma viral oncogene/mammalian target of rapamycin) pathway in bladder urothelial carcinoma.
    Korkolopoulou P; Levidou G; Trigka EA; Prekete N; Karlou M; Thymara I; Sakellariou S; Fragkou P; Isaiadis D; Pavlopoulos P; Patsouris E; Saetta AA
    BJU Int; 2012 Dec; 110(11 Pt C):E1237-48. PubMed ID: 23107319
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Androgens stimulate hypoxia-inducible factor 1 activation via autocrine loop of tyrosine kinase receptor/phosphatidylinositol 3'-kinase/protein kinase B in prostate cancer cells.
    Mabjeesh NJ; Willard MT; Frederickson CE; Zhong H; Simons JW
    Clin Cancer Res; 2003 Jul; 9(7):2416-25. PubMed ID: 12855613
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Arachidonic acid activates phosphatidylinositol 3-kinase signaling and induces gene expression in prostate cancer.
    Hughes-Fulford M; Li CF; Boonyaratanakornkit J; Sayyah S
    Cancer Res; 2006 Feb; 66(3):1427-33. PubMed ID: 16452198
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Id-1 activation of PI3K/Akt/NFkappaB signaling pathway and its significance in promoting survival of esophageal cancer cells.
    Li B; Cheung PY; Wang X; Tsao SW; Ling MT; Wong YC; Cheung AL
    Carcinogenesis; 2007 Nov; 28(11):2313-20. PubMed ID: 17638919
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Development of a three-dimensional culture model of prostatic epithelial cells and its use for the study of epithelial-mesenchymal transition and inhibition of PI3K pathway in prostate cancer.
    Chu JH; Yu S; Hayward SW; Chan FL
    Prostate; 2009 Mar; 69(4):428-42. PubMed ID: 19107869
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Immunohistochemical examination of the mTORC1 pathway in high grade prostatic intraepithelial neoplasia (HGPIN) and prostatic adenocarcinomas (PCa): a tissue microarray study (TMA).
    Evren S; Dermen A; Lockwood G; Fleshner N; Sweet J
    Prostate; 2010 Sep; 70(13):1429-36. PubMed ID: 20687216
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Akt-mediated phosphorylation of Bmi1 modulates its oncogenic potential, E3 ligase activity, and DNA damage repair activity in mouse prostate cancer.
    Nacerddine K; Beaudry JB; Ginjala V; Westerman B; Mattiroli F; Song JY; van der Poel H; Ponz OB; Pritchard C; Cornelissen-Steijger P; Zevenhoven J; Tanger E; Sixma TK; Ganesan S; van Lohuizen M
    J Clin Invest; 2012 May; 122(5):1920-32. PubMed ID: 22505453
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Role of the phosphatidylinositol 3'-kinase/PTEN/Akt kinase pathway in the overexpression of fatty acid synthase in LNCaP prostate cancer cells.
    Van de Sande T; De Schrijver E; Heyns W; Verhoeven G; Swinnen JV
    Cancer Res; 2002 Feb; 62(3):642-6. PubMed ID: 11830512
    [TBL] [Abstract][Full Text] [Related]  

  • 31. [Effect of PI3K/AKT inhibitor on benign prostate hyperplasia and its mechanism: an experimental study].
    Jin P; Wang YH; Peng YG; Hu S; Lu Q; Yang LY
    Zhonghua Nan Ke Xue; 2010 Dec; 16(12):1068-75. PubMed ID: 21348195
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Longitudinal inhibition of PI3K/Akt/mTOR signaling by LY294002 and rapamycin induces growth arrest of adult T-cell leukemia cells.
    Ikezoe T; Nishioka C; Bandobashi K; Yang Y; Kuwayama Y; Adachi Y; Takeuchi T; Koeffler HP; Taguchi H
    Leuk Res; 2007 May; 31(5):673-82. PubMed ID: 17007924
    [TBL] [Abstract][Full Text] [Related]  

  • 33. AKT and mTOR phosphorylation is frequently detected in ovarian cancer and can be targeted to disrupt ovarian tumor cell growth.
    Altomare DA; Wang HQ; Skele KL; De Rienzo A; Klein-Szanto AJ; Godwin AK; Testa JR
    Oncogene; 2004 Jul; 23(34):5853-7. PubMed ID: 15208673
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Reverse phase protein microarrays which capture disease progression show activation of pro-survival pathways at the cancer invasion front.
    Paweletz CP; Charboneau L; Bichsel VE; Simone NL; Chen T; Gillespie JW; Emmert-Buck MR; Roth MJ; Petricoin III EF; Liotta LA
    Oncogene; 2001 Apr; 20(16):1981-9. PubMed ID: 11360182
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Prolactin activates mammalian target-of-rapamycin through phosphatidylinositol 3-kinase and stimulates phosphorylation of p70S6K and 4E-binding protein-1 in lymphoma cells.
    Bishop JD; Nien WL; Dauphinee SM; Too CK
    J Endocrinol; 2006 Aug; 190(2):307-12. PubMed ID: 16899564
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Effects of ras and von Hippel-Lindau (VHL) gene mutations on hypoxia-inducible factor (HIF)-1alpha, HIF-2alpha, and vascular endothelial growth factor expression and their regulation by the phosphatidylinositol 3'-kinase/Akt signaling pathway.
    Blancher C; Moore JW; Robertson N; Harris AL
    Cancer Res; 2001 Oct; 61(19):7349-55. PubMed ID: 11585776
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Modulation of phosphatidylinositol-3-kinase/protein kinase B- and mitogen-activated protein kinase-pathways by tea polyphenols in human prostate cancer cells.
    Siddiqui IA; Adhami VM; Afaq F; Ahmad N; Mukhtar H
    J Cell Biochem; 2004 Feb; 91(2):232-42. PubMed ID: 14743383
    [TBL] [Abstract][Full Text] [Related]  

  • 38. WJD008, a dual phosphatidylinositol 3-kinase (PI3K)/mammalian target of rapamycin inhibitor, prevents PI3K signaling and inhibits the proliferation of transformed cells with oncogenic PI3K mutant.
    Li T; Wang J; Wang X; Yang N; Chen SM; Tong LJ; Yang CH; Meng LH; Ding J
    J Pharmacol Exp Ther; 2010 Sep; 334(3):830-8. PubMed ID: 20522531
    [TBL] [Abstract][Full Text] [Related]  

  • 39. [P2Y purinergic receptor activated PI-3K/Akt signaling pathway in regulation of growth and invasion of prostatic cancer].
    Wang YX; Shi YH; Gong LH; Li Y; Heng WJ; You JF; Zhong HH; Fang WG
    Zhonghua Bing Li Xue Za Zhi; 2007 Oct; 36(10):681-6. PubMed ID: 18194602
    [TBL] [Abstract][Full Text] [Related]  

  • 40. MNK2 inhibits eIF4G activation through a pathway involving serine-arginine-rich protein kinase in skeletal muscle.
    Hu SI; Katz M; Chin S; Qi X; Cruz J; Ibebunjo C; Zhao S; Chen A; Glass DJ
    Sci Signal; 2012 Feb; 5(211):ra14. PubMed ID: 22337810
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 5.